
Safusidenib showed durable responses in IDH1-mutant glioma, and ongoing trials will test the agent in oligodendroglioma, after vorasidenib, and as maintenance.
October 2008, Vol 22 No 11
Main Articles
Psychological Challenges After Cancer: A Guide for Clinical Practice Reviewed in:
The Recklitis et al Article Reviewed
LATE EFFECTS CLINIC: Post-Trauma Symptoms in Cancer Survivors
Graft-Versus-Host Disease: A Complex Long-Term Side Effect of Hematopoietic Stem Cell Transplant Reviewed in:
The Barton-Burke et al Article Reviewed
DRUG ESSENTIALS: Small Molecule Multitargeted TKI Therapy
PATIENT INFORMATION: Fatigue in People with Cancer
about 18 years ago
The Recklitis et al Article Reviewedabout 18 years ago
A Challenge of Survivorship-Healing the Mind and Spiritabout 18 years ago
Post-Trauma Symptoms in Cancer Survivorsabout 18 years ago
Small Molecule Multitargeted TKI Therapyabout 18 years ago
La fatiga en personas con cáncerabout 18 years ago
Fatigue in People With Cancer





